Victor Yip
Overview
Explore the profile of Victor Yip including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
321
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yip V, Saad O, Leipold D, Li C, Kamath A, Shen B
Xenobiotica
. 2024 Apr;
54(8):511-520.
PMID: 38647387
Monomethyl auristatin E (MMAE) has been used as a payload for several Food and Drug Administration (FDA) approved antibody-drug conjugates (ADCs). It is known that MMAE is released from the...
2.
Yadav R, Sukumaran S, Lutman J, Mitra M, Halpern W, Sun T, et al.
J Pharm Sci
. 2023 Jul;
112(11):2910-2920.
PMID: 37429356
MTBT1466A is a high-affinity TGFβ3-specific humanized IgG1 monoclonal antibody with reduced Fc effector function, currently under investigation in clinical trials as a potential anti-fibrotic therapy. Here, we characterized the pharmacokinetics...
3.
Zacharias N, Podust V, Kajihara K, Leipold D, Rosario G, Thayer D, et al.
Chem Sci
. 2022 Apr;
13(11):3147-3160.
PMID: 35414872
The antibody-drug conjugate (ADC) is a well-validated modality for the cell-specific delivery of small molecules with impact expanding rapidly beyond their originally-intended purpose of treating cancer. However, antibody-mediated delivery (AMD)...
4.
Yip V, Lee M, Saad O, Ma S, Khojasteh S, Shen B
J Clin Med
. 2021 Apr;
10(6).
PMID: 33806916
Polatuzumab vedotin (or POLIVY), an antibody-drug conjugate (ADC) composed of a polatuzumab monoclonal antibody conjugated to monomethyl auristatin E (MMAE) via a cleavable dipeptide linker, has been approved by the...
5.
Yip V, Figueroa I, Latifi B, Masih S, Ng C, Leipold D, et al.
Drug Metab Dispos
. 2020 Oct;
48(12):1247-1256.
PMID: 33020064
Anti-Ly6E--cyclopropabenzindol-4-one dimer antibody-drug conjugate (ADC) has been reported to form an adduct with 1-microglobulin (A1M) in animal plasma, but with unknown impact on ADC PK and tissue distribution. In this...
6.
Cai H, Yip V, Lee M, Wong S, Saad O, Ma S, et al.
Drug Metab Dispos
. 2020 Aug;
48(11):1161-1168.
PMID: 32839277
Invasive infection is a leading cause of infectious disease-related deaths because survives within host phagocytic cells, from which the bacteria are not adequately eliminated using current antibiotic treatments. Anti- THIOMAB...
7.
Lombana T, Rajan S, Zorn J, Mandikian D, Chen E, Estevez A, et al.
MAbs
. 2019 May;
11(6):1122-1138.
PMID: 31122132
IgA antibodies have broad potential as a novel therapeutic platform based on their superior receptor-mediated cytotoxic activity, potent neutralization of pathogens, and ability to transcytose across mucosal barriers via polymeric...
8.
Leipold D, Figueroa I, Masih S, Latifi B, Yip V, Shen B, et al.
MAbs
. 2018 Sep;
10(8):1312-1321.
PMID: 30183491
Few treatment options are available for acute myeloid leukemia (AML) patients. DCLL9718A is an antibody-drug conjugate that targets C-type lectin-like molecule-1 (CLL-1). This receptor is prevalent on monocytes, neutrophils, and...
9.
Dickmann L, Yip V, Li C, Abundes Jr J, Maia M, Young C, et al.
Invest Ophthalmol Vis Sci
. 2015 Oct;
56(11):6991-9.
PMID: 26513505
Purpose: In this work, we assessed the ability of fluorophotometry to measure the vitreal pharmacokinetics (PK) of fluorescently-labeled ranibizumab in the rabbit after intravitreal injection. We compared these values to...
10.
Wei Z, Nguyen M, OMahony D, Acevedo A, Zipfel S, Zhang Q, et al.
Bioorg Med Chem Lett
. 2015 Aug;
25(18):4011-5.
PMID: 26235950
Antagonists of the TRPV4 receptor were identified using a focused screen, followed by a limited optimization program. The leading compounds obtained from this exercise, RN-1665 23 and RN-9893 26, showed...